Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004359|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
OBJECTIVES: I. Evaluate immunomodulation with extracorporeal photochemotherapy (ECP) in patients with epidermolysis bullosa acquisita.
II. Investigate the effect of ECP on lymphocyte activity.
|Condition or disease||Intervention/treatment||Phase|
|Epidermolysis Bullosa Acquisita||Drug: methoxsalen||Phase 2|
PROTOCOL OUTLINE: Oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis. Blood mononuclear cells are exposed to ultraviolet A light for 3 hours, then returned to the patient. The process is repeated on 2 successive days.
Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Study Start Date :||February 1996|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004359
|Study Chair:||Kenneth B. Gordon||Northwestern University|